secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lexeo Therapeutics, Inc. (LXEO)
CIK:        0001907108
Form:       8-K
Filed at:   2024-02-05T23:59:59+00:00
Accession:  0000950170-24-011005
Event type: leadership
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexeo appoints CDO, CMO, Senior Advisor, and Chief Business & Legal Officer
---------------------------------------------------------------------------

- Sandi See Tai promoted to Chief Development Officer; previously VP at Pfizer, led tafamidis ATTR-ACT program.
- Eric Adler appointed Chief Medical Officer & Head of Research; former CSO at Lexeo, UCSD professor, gene therapy pioneer.
- Rajiv Patni named Senior Advisor to CEO & Board; former CRO at Reata (acquired by Biogen), led Skyclarys approval.
- Jenny Robertson promoted to Chief Business and Legal Officer; previously Chief Legal & Admin Officer, Pfizer rare disease counsel.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1907108/000095017024011005/0000950170-24-011005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1907108/000095017024011005/lxeo-20240205.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-011005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer